TY  - JOUR
AU  - Malfertheiner, Peter
AU  - Megraud, Francis
AU  - Rokkas, Theodore
AU  - Gisbert, Javier P.
AU  - Liou, Jyh-Ming
AU  - Schulz, Christian
AU  - Gasbarrini, Antonio
AU  - Hunt, Richard H.
AU  - Leja, Marcis
AU  - O’Morain, Colm
AU  - Rugge, Massimo
AU  - Suerbaum, Sebastian
AU  - Tilg, Herbert
AU  - Sugano, Kentaro
AU  - El-Omar, Emad M.
AU  - Agreus, L.
AU  - Bazzoli, F
AU  - Bordin, D
AU  - Loginov, A.S.
AU  - Mario, F. D.
AU  - Dinis-Ribeiro, M.
AU  - Engstrand, Lars
AU  - Fallone, C
AU  - Goh, K.L.
AU  - Graham, David
AU  - Kuipers, E.J.
AU  - Kupcinskas, J.
AU  - Lanas, A.
AU  - Machado, Jose C.
AU  - Mahachai, V.
AU  - Marshall, B.J.
AU  - Milosavljevic, Tomica
AU  - Moss, S.F.
AU  - Park, J.Y.
AU  - Niv, Y.
AU  - Rajilić-Stojanović, Mirjana
AU  - Ristimaki, A
AU  - Smith, S.
AU  - Tepeš, Bojan
AU  - Wu, C.Y.
AU  - Zhou, L.
PY  - 2022
UR  - http://TechnoRep.tmf.bg.ac.rs/handle/123456789/6050
AB  - elicobacter pylori Infection is formally recognised as an infectious disease, an entity that is now included in the International Classification of Diseases 11th Revision. This in principle leads to the recommendation that all infected patients should receive treatment. In the context of the wide clinical spectrum associated with Helicobacter pylori gastritis, specific issues persist and require regular updates for optimised management. The identification of distinct clinical scenarios, proper testing and adoption of effective strategies for prevention of gastric cancer and other complications are addressed. H. pylori treatment is challenged by the continuously rising antibiotic resistance and demands for susceptibility testing with consideration of novel molecular technologies and careful selection of first line and rescue therapies. The role of H. pylori and antibiotic therapies and their impact on the gut microbiota are also considered. Progress made in the management of H. pylori infection is covered in the present sixth edition of the Maastricht/ Florence 2021 Consensus Report, key aspects related to the clinical role of H. pylori infection were re-evaluated and updated. Forty-one experts from 29 countries representing a global community, examined the new data related to H. pylori infection in five working groups: (1) indications/associations, (2) diagnosis, (3) treatment, (4) prevention/gastric cancer and (5) H. pylori and the gut microbiota. The results of the individual working groups were presented for a final consensus voting that included all participants. Recommendations are provided on the basis of the best available evidence and relevance to the management of H. pylori infection in various clinical fields.
PB  - BMJ Publishing Group
T2  - Guidelines
T1  - Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report
EP  - 1762
IS  - 9
SP  - 1724
VL  - 71
DO  - 10.1136/gutjnl-2022-327745
ER  - 

@article{
author = "Malfertheiner, Peter and Megraud, Francis and Rokkas, Theodore and Gisbert, Javier P. and Liou, Jyh-Ming and Schulz, Christian and Gasbarrini, Antonio and Hunt, Richard H. and Leja, Marcis and O’Morain, Colm and Rugge, Massimo and Suerbaum, Sebastian and Tilg, Herbert and Sugano, Kentaro and El-Omar, Emad M. and Agreus, L. and Bazzoli, F and Bordin, D and Loginov, A.S. and Mario, F. D. and Dinis-Ribeiro, M. and Engstrand, Lars and Fallone, C and Goh, K.L. and Graham, David and Kuipers, E.J. and Kupcinskas, J. and Lanas, A. and Machado, Jose C. and Mahachai, V. and Marshall, B.J. and Milosavljevic, Tomica and Moss, S.F. and Park, J.Y. and Niv, Y. and Rajilić-Stojanović, Mirjana and Ristimaki, A and Smith, S. and Tepeš, Bojan and Wu, C.Y. and Zhou, L.",
year = "2022",
abstract = "elicobacter pylori Infection is formally recognised as an infectious disease, an entity that is now included in the International Classification of Diseases 11th Revision. This in principle leads to the recommendation that all infected patients should receive treatment. In the context of the wide clinical spectrum associated with Helicobacter pylori gastritis, specific issues persist and require regular updates for optimised management. The identification of distinct clinical scenarios, proper testing and adoption of effective strategies for prevention of gastric cancer and other complications are addressed. H. pylori treatment is challenged by the continuously rising antibiotic resistance and demands for susceptibility testing with consideration of novel molecular technologies and careful selection of first line and rescue therapies. The role of H. pylori and antibiotic therapies and their impact on the gut microbiota are also considered. Progress made in the management of H. pylori infection is covered in the present sixth edition of the Maastricht/ Florence 2021 Consensus Report, key aspects related to the clinical role of H. pylori infection were re-evaluated and updated. Forty-one experts from 29 countries representing a global community, examined the new data related to H. pylori infection in five working groups: (1) indications/associations, (2) diagnosis, (3) treatment, (4) prevention/gastric cancer and (5) H. pylori and the gut microbiota. The results of the individual working groups were presented for a final consensus voting that included all participants. Recommendations are provided on the basis of the best available evidence and relevance to the management of H. pylori infection in various clinical fields.",
publisher = "BMJ Publishing Group",
journal = "Guidelines",
title = "Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report",
pages = "1762-1724",
number = "9",
volume = "71",
doi = "10.1136/gutjnl-2022-327745"
}

Malfertheiner, P., Megraud, F., Rokkas, T., Gisbert, J. P., Liou, J., Schulz, C., Gasbarrini, A., Hunt, R. H., Leja, M., O’Morain, C., Rugge, M., Suerbaum, S., Tilg, H., Sugano, K., El-Omar, E. M., Agreus, L., Bazzoli, F., Bordin, D., Loginov, A.S., Mario, F. D., Dinis-Ribeiro, M., Engstrand, L., Fallone, C., Goh, K.L., Graham, D., Kuipers, E.J., Kupcinskas, J., Lanas, A., Machado, J. C., Mahachai, V., Marshall, B.J., Milosavljevic, T., Moss, S.F., Park, J.Y., Niv, Y., Rajilić-Stojanović, M., Ristimaki, A., Smith, S., Tepeš, B., Wu, C.Y.,& Zhou, L.. (2022). Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. in Guidelines
BMJ Publishing Group., 71(9), 1724-1762.
https://doi.org/10.1136/gutjnl-2022-327745

Malfertheiner P, Megraud F, Rokkas T, Gisbert JP, Liou J, Schulz C, Gasbarrini A, Hunt RH, Leja M, O’Morain C, Rugge M, Suerbaum S, Tilg H, Sugano K, El-Omar EM, Agreus L, Bazzoli F, Bordin D, Loginov A, Mario FD, Dinis-Ribeiro M, Engstrand L, Fallone C, Goh K, Graham D, Kuipers E, Kupcinskas J, Lanas A, Machado JC, Mahachai V, Marshall B, Milosavljevic T, Moss S, Park J, Niv Y, Rajilić-Stojanović M, Ristimaki A, Smith S, Tepeš B, Wu C, Zhou L. Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report. in Guidelines. 2022;71(9):1724-1762.
doi:10.1136/gutjnl-2022-327745 .

Malfertheiner, Peter, Megraud, Francis, Rokkas, Theodore, Gisbert, Javier P., Liou, Jyh-Ming, Schulz, Christian, Gasbarrini, Antonio, Hunt, Richard H., Leja, Marcis, O’Morain, Colm, Rugge, Massimo, Suerbaum, Sebastian, Tilg, Herbert, Sugano, Kentaro, El-Omar, Emad M., Agreus, L., Bazzoli, F, Bordin, D, Loginov, A.S., Mario, F. D., Dinis-Ribeiro, M., Engstrand, Lars, Fallone, C, Goh, K.L., Graham, David, Kuipers, E.J., Kupcinskas, J., Lanas, A., Machado, Jose C., Mahachai, V., Marshall, B.J., Milosavljevic, Tomica, Moss, S.F., Park, J.Y., Niv, Y., Rajilić-Stojanović, Mirjana, Ristimaki, A, Smith, S., Tepeš, Bojan, Wu, C.Y., Zhou, L., "Management of Helicobacter pylori infection: the Maastricht VI/Florence consensus report" in Guidelines, 71, no. 9 (2022):1724-1762,
https://doi.org/10.1136/gutjnl-2022-327745 . .